AppLovin GLP-1 ads sit under restricted content: AppLovin lists prescription drugs as restricted, not prohibited, and they run only with express approval from the AppLovin team. Telemedicine advertisers also need third-party certification such as LegitScript, adult-only targeting, and prescription ads aimed only at the US, Canada or New Zealand.
Policy checked on October 29, 2026.
What AppLovin’s policy says about GLP-1 and prescription drugs
AppLovin’s Policies for Demand Partners (date updated October 25, 2026) put health products in the Restricted Content list, which reads:
“Health, wellness, and pharmaceutical products and services, including prescription drugs.”
The permission clause for every restricted category says advertisers “may be permitted, in AppLovin’s sole discretion, to use the Services to deliver ads containing any of the following restricted content categories”, provided the ads follow the laws of each targeted market. It then sets the route: “you must notify the AppLovin account team and obtain approval before attempting to serve the ad through the Services.”
The separate health guideline (date updated February 27, 2026) repeats the condition: the advertiser must “obtain express approval from the AppLovin Team.” For telehealth it adds:
“Advertisers for online pharmacies, telemedicine, certain medical devices, and similar services must be certified by recognized third-party authorities (e.g., LegitScript) before serving ads and provide proof of certification on request.”
Neither page names GLP-1, semaglutide or tirzepatide, so a GLP-1 telehealth offer is read against the general health and prescription-drug rules.
The same guideline lists 11 categories AppLovin does “not support”, and ads and their landing pages “may not promote or attempt to promote them”. The first category on that list is “Drugs for chronic or life-threatening diseases”. AppLovin does not say whether GLP-1 falls under it. Restricted content runs “in AppLovin’s sole discretion”, so that call is AppLovin’s.
AppLovin’s health rules mapped to a GLP-1 telehealth campaign
This table takes each line of the February 27, 2026 health guideline and applies it to a GLP-1 weight-loss program. Quotes are AppLovin’s.
| Campaign element | What AppLovin’s rule says | What it means for a GLP-1 brand |
|---|---|---|
| Account | “express approval from the AppLovin Team” | No GLP-1 ad serves before the account team signs off |
| Certification | Telemedicine “must be certified by recognized third-party authorities (e.g., LegitScript)” | Certification in place before launch, proof on request |
| Licenses | “all necessary authorizations and licenses” per targeted jurisdiction | Target only states where your clinicians and pharmacy can serve |
| Geography | Rx ads “may only target” Canada, New Zealand, United States | US campaigns only for a US brand |
| Age | “Advertisers may not target individuals under the age of 18.” | Adults only |
| Drug names in creative | FDA-approved product ads need “approved labels and applicable warnings” and approved uses only | Keep drug names out of creative |
| Weight-loss claims | Ads may not “claim or promote unrealistic weight loss” | No pounds-lost promises |
| Copy voice | No implied “knowledge of a user’s personal health status”, including “you” or “your” | “Lose your belly fat” fails; program-level copy is the safer line |
| Before and after | No imagery with “unlikely or extreme results” or body-part focus | No transformation shots, no zoomed body parts |
| Body image | No ads that “exploit insecurities” or reinforce “unhealthy body images” | Lead with access and the program |
| Regulatory history | No products “subject to any government or regulatory action, warning, or advisory” | A product that has drawn an FDA warning letter or a state attorney general action is out |
| Data | Ads can’t request health information; no protected health information to AppLovin | Pixel events stay non-health (see health data and tracking) |
| Landing page | Must carry required labels and disclaimers and avoid non-compliant content | The landing page is reviewed with the ad |
For the claims side of compounded GLP-1 offers, see what the FDA calls misleading in GLP-1 ads.
AppLovin Ads, Axon and where the ads run
AppLovin’s self-serve platform launched on a referral basis in October 2025 under the Axon name (“we called it Axon”). On June 22, 2026, AppLovin opened it to every advertiser and renamed it. CEO Adam Foroughi wrote: “our ad platform is simply called AppLovin Ads”, and “Axon remains the name of our AI recommendation system.”
- Access until October 2025: “For 14 years, advertising with AppLovin required a relationship with our team.”
- Reach: AppLovin says any business can now “reach our billion-plus daily active users” (June 22, 2026).
- Who can buy: AppLovin’s support FAQ says it serves “web and app businesses”, so a telehealth site can run web campaigns.
- Placements: “Ads appear across a variety of top-rated mobile games, including Candy Crush, Sudoku, Solitaire, and Words With Friends.”
For a GLP-1 brand the ad shows inside a game, not a social feed, so the creative has to explain the program in seconds and the landing page carries the detail.
How AppLovin reviews ads and what happens on a rejection
AppLovin says every advertiser goes through an account approval process with “verification techniques and other measures”. After that, “Our systems use a mix of automated tools and manual review” for each ad. The tools check images, video, text and the landing page, and AppLovin also reviews “your overall domain and assets.”
| Status | AppLovin’s meaning |
|---|---|
| In review | Not yet reviewed |
| Approved | Can be added to creative sets and serve |
| Rejected | Violates the identified policies |
AppLovin’s Platform Enforcement page adds that accounts its tools flag for repeat policy violations “will be subject to suspension or termination.” The official routes, per AppLovin’s policy introduction:
- Rejected ad: review the Policies for Demand Partners and “create a new ad that complies”.
- Suspended account: review the Terms of Use Agreement and the Policies for Demand Partners; if you believe the suspension was in error, “reach out to your account manager or contact AppLovin Support”.
How GLP1.partners runs AppLovin for GLP-1 brands
AppLovin is one of the networks we buy for GLP-1 brands, alongside TikTok, Outbrain and Meta, next to our own comparison sites and an affiliate network we manage. We run GLP-1 and telehealth traffic at scale with platform approvals on every network we buy. We plan and buy the media; the details of how we’d run your offer are covered on a call.
What your brand still brings to an AppLovin campaign:
- Certification: LegitScript (or equivalent) certification for your telehealth service. See also LegitScript requirements by ad platform.
- Licenses: proof you can prescribe and ship in each state we target.
- Claims support: substantiation for every claim on the ad and landing page.
- A compliant landing page: the labels, warnings and disclaimers AppLovin’s guideline requires.
- Clean tracking: no protected health information in pixel events.
FAQ
Can you advertise GLP-1 on AppLovin?
Only with AppLovin’s approval. Prescription drugs are restricted on AppLovin, not prohibited. The AppLovin team must give express approval, telemedicine advertisers must be certified (AppLovin names LegitScript as an example), and prescription ads may target only the US, Canada and New Zealand. AppLovin’s list of unsupported health products includes “Drugs for chronic or life-threatening diseases” and does not say whether GLP-1 falls under it.
Is AppLovin Ads the same as Axon?
AppLovin Ads is the self-serve platform AppLovin launched in October 2025 under the name Axon. It took the AppLovin Ads name on June 22, 2026, and Axon is now the name of AppLovin’s AI recommendation system.
Are weight-loss ads allowed on AppLovin?
Weight-loss ads fall under the health guideline. Ads may not promote unrealistic weight loss, use extreme before-and-after imagery or target people under 18.
Sources
- AppLovin, Policies for Demand Partners (Restricted Content; date updated October 25, 2026, October 26, 2026 revision listed) · accessed
- AppLovin, Restricted Content: Health, Wellness, and Pharmaceutical Products (date updated February 27, 2026) · accessed
- AppLovin, Introduction to AppLovin's Ad Content Policies (Ads Manager review, statuses, rejected and suspended steps) · accessed
- AppLovin, Platform Enforcement (account approval process, automated ad review) · accessed
- AppLovin blog, AppLovin Ads is now open to all advertisers (June 22, 2026) · accessed
- AppLovin Support, Promoting your websites FAQ (web and app businesses, mobile-game placements) · accessed